Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,223,280
  • Shares Outstanding, K 2,508,090
  • Annual Sales, $ 40,921 M
  • Annual Income, $ 4,285 M
  • 36-Month Beta 0.85
  • Price/Sales 2.54
  • Price/Cash Flow 8.42
  • Price/Book 1.54

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.17 +2.61%
on 03/26/18
41.50 -3.15%
on 04/10/18
+0.86 (+2.20%)
since 03/23/18
3-Month
38.14 +5.39%
on 02/09/18
45.86 -12.35%
on 01/26/18
-3.55 (-8.11%)
since 01/23/18
52-Week
38.14 +5.39%
on 02/09/18
50.65 -20.64%
on 09/22/17
-3.90 (-8.84%)
since 04/21/17

Most Recent Stories

More News
Shire (SHPG) Turns Down Takeda's Third Buyout Proposition

Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.

AGN : 160.54 (+1.28%)
NVS : 77.85 (-0.04%)
SHPG : 160.76 (-2.20%)
SNY : 40.17 (+0.53%)
Sanofi to Divest European Generic Unit, Streamline Business

Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

NVS : 77.85 (-0.04%)
SHPG : 160.76 (-2.20%)
GSK : 40.23 (+0.57%)
SNY : 40.17 (+0.53%)
Model N Founder & CEO Zack Rinat Named Ernst & Young 2018 Entrepreneur of the Year Semifinalist

Model N, Inc. (NYSE: MODN), the leading provider of revenue management solutions for the pharmaceutical, medical device, high tech, manufacturing and semiconductor industries, announced that...

ABT : 58.92 (-0.46%)
AZN : 35.45 (+0.31%)
STX : 58.51 (-1.89%)
NXPI : 104.55 (-0.57%)
MODN : 17.33 (-1.81%)
AMD : 10.02 (+0.30%)
MU : 49.47 (-2.27%)
GILD : 73.79 (+0.12%)
STM : 21.26 (-1.12%)
PFE : 36.77 (+0.38%)
SNY : 40.17 (+0.53%)
Top Analyst Reports for AbbVie, Berkshire & PepsiCo

Top Analyst Reports for AbbVie, Berkshire & PepsiCo

FOXA : 36.60 (-0.22%)
BRK.B : 199.68 (-0.22%)
PEP : 102.45 (-0.03%)
ABBV : 93.19 (+0.64%)
BP : 43.65 (+0.34%)
SNY : 40.17 (+0.53%)
Sanofi to invest ?350 million in Canadian vaccine facility

Sanofi to invest €350 million in Canadian vaccine facility

SAN : 6.80 (+0.29%)
SNY : 40.17 (+0.53%)
Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.

CELG : 89.28 (+0.37%)
GILD : 73.79 (+0.12%)
SNY : 40.17 (+0.53%)
ALXN : 108.76 (+0.91%)
New tools, support and information on insulin use now available to Canadians living with Type 2 diabetes aiming to maintain healthy blood glucose levels

New tools, support and information on insulin use now available to Canadians living with Type 2 diabetes aiming to maintain healthy blood glucose levels

SAN : 6.80 (+0.29%)
SNY : 40.17 (+0.53%)
New Sanofi insulin savings program aims to lower out-of-pocket costs for people living with diabetes

Sanofi's new Insulins VALyou Savings Program will seek to help lower out-of-pocket costs for people living with diabetes who otherwise would pay full retail price for Lantus or Admelog. This includes certain...

SAN : 6.80 (+0.29%)
SNY : 40.17 (+0.53%)
Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion

The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.

REGN : 315.57 (+0.42%)
ALKS : 45.56 (-1.00%)
AMGN : 174.89 (+1.94%)
EDGE : 1.27 (+11.40%)
SNY : 40.17 (+0.53%)
Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU

Sanofi's (SNY) filing for its antibody cemiplimab for skin cancer and the label expansion of its marketed drug Dupixent for asthama wins acceptance from EMA.

LGND : 165.79 (-0.71%)
ENTA : 87.40 (-0.10%)
REGN : 315.57 (+0.42%)
SNY : 40.17 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 40.23
1st Resistance Point 40.10
Last Price 40.17
1st Support Level 39.87
2nd Support Level 39.77

See More

52-Week High 50.65
Fibonacci 61.8% 45.87
Fibonacci 50% 44.40
Fibonacci 38.2% 42.92
Last Price 40.17
52-Week Low 38.14

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar